Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects

详细信息    查看全文

• 作者：Yi Han ; Surya Ayalasomayajula ; Wei Pan…
• 刊名：European Journal of Drug Metabolism and Pharmacokinetics
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：42
• 期：1
• 页码：109-116
• 全文大小：
• 刊物主题：Pharmacology/Toxicology; Pharmacy; Human Physiology; Pharmaceutical Sciences/Technology; Medical Biochemistry;
• 出版者：Springer International Publishing
• ISSN：2107-0180
• 卷排序：42

文摘

Background and ObjectiveSacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) and has been recently approved in several countries for the treatment of patients with heart failure and reduced ejection fraction. This was the first study conducted to characterise the pharmacokinetics of LCZ696 analytes (pro-drug sacubitril, active neprilysin inhibitor LBQ657 and valsartan) after single-dose administration of LCZ696 in healthy Chinese subjects.